A 4-Week, Phase II, Randomized, Double-Blind, Dose-Ranging, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety, Efficacy and Pharmacokinetics of GSK1278863 in Japanese Hemodialysis-Dependent Subjects With Anemia Associated With Chronic Kidney Disease
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2018
Price : $35 *
At a glance
- Drugs Daprodustat (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 31 Aug 2018 Biomarkers information updated
- 15 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2014 Planned End Date changed from 1 Jul 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.